Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology

被引：10
作者：
Kaimakliotis, Hristos Z. [1 ]
Monn, M. Francesca [1 ]
Cho, Jane S. [1 ]
Pedrosa, Jose A. [1 ]
Hahn, Noah M. [2 ]
Albany, Costantine [3 ]
Gellhaus, Paul T. [1 ]
Cary, K. Clint [1 ]
Masterson, Timothy A. [1 ]
Foster, Richard S. [1 ]
Bihrle, Richard [1 ]
Cheng, Liang [3 ]
Koch, Michael O. [1 ]
机构：
[1] Indiana Univ Sch Med, Dept Urol, 535 Barnhill Dr, Indianapolis, IN 46202 USA
[2] Johns Hopkins Sch Med, Dept Genitourinary Med Oncol, 1550 Orleans St,Room 1M51, Baltimore, MD 21287 USA
[3] Indiana Univ Sch Med, Dept Genitourinary Med Oncol, 535 Barnhill Dr, Indianapolis, IN 46202 USA
来源：
FUTURE ONCOLOGY | 2016年 / 12卷 / 15期
关键词：
GEMCITABINE PLUS CISPLATIN; RADICAL CYSTECTOMY; POOR-PROGNOSIS; PHASE-III; CARCINOMA; METHOTREXATE; VINBLASTINE; DOXORUBICIN; SURVIVAL; METAANALYSIS;
D O I：
10.2217/fon-2016-0056
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: We compared the efficacy of methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) versus gemcitabine/cisplatin in urothelial cancer and neoadjuvant chemotherapy (NACT) efficacy in variant histology (VH). Materials & methods: Radical cystectomy patients were retrospectively compared with those who received NACT. Factors associated with survival, pathologic complete response (pCR) and downstaging (pDS) were evaluated in multivariable models. Results: 9% of radical cystectomy patients (84/919) received NACT, with improved survival, pCR and pDS on both regimens. MVAC lead to higher pDS without an increase in pCR. On multivariable analysis, there was a nonsignificant increase in pDS with MVAC. NACT conferred similar responses in squamous and glandular differentiation VH. Conclusion: NACT was associated with improved survival, pCR and pDS. Furthermore, responses to NACT were not dependent on presence of VH.
引用
收藏
页码：1795 / 1804
页数：10
相关论文
共 50 条
  • [31] Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer
    Henon, Clemence
    Huillard, Olivier
    Preta, Laure-Helene
    Blanchet, Benoit
    Goldwasser, Francois
    Alexandre, Jerome
    CLINICAL GENITOURINARY CANCER, 2017, 15 (03) : E493 - E495
  • [32] Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience
    El-Gehani, Faraj
    North, Scott
    Ghosh, Sunita
    Venner, Peter
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2014, 8 (3-4): : E287 - E293
  • [33] Impact of neoadjuvant chemotherapy on therapeutic management of muscle-invasive bladder cancer
    Meyer, V.
    Flechon, A.
    Tartas, S.
    Fassi-Fehri, H.
    Ruffion, A.
    Martin, X.
    Colombel, M.
    PROGRES EN UROLOGIE, 2015, 25 (02): : 83 - 89
  • [34] Chemotherapy regimen is associated with venous thromboembolism risk in patients with urothelial tract cancer
    Ramos, Jorge D.
    Holt, Sarah K.
    Schade, George R.
    Galsky, Matthew D.
    Wright, Jonathan L.
    Gore, John L.
    Yu, Evan Y.
    BJU INTERNATIONAL, 2019, 124 (02) : 290 - 296
  • [35] A prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder cancer
    Kato, Yoichiro
    Zembutsu, Hitoshi
    Takata, Ryo
    Matsuura, Tomohiko
    Kato, Renpei
    Kanehira, Mitsugu
    Iwasaki, Kazuhiro
    Yamada, Noriyuki
    Katagiri, Toyomasa
    Sugai, Tamotsu
    Fujioka, Tomoaki
    Nakamura, Yusuke
    Obara, Wataru
    ONCOLOGY LETTERS, 2018, 16 (05) : 5775 - 5784
  • [36] Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer
    D'Andrea, David
    Black, Peter C.
    Zargar, Homayoun
    Zargar-Shoshtari, Kamran
    Zehetmayer, Sonja
    Fairey, Adrian S.
    Mertens, Laura S.
    Dinney, Colin P.
    Mir, Maria C.
    Krabbe, Laura-Maria
    Cookson, Michael S.
    Jacobsen, Niels-Erik
    Montgomery, Jeffrey S.
    Vasdev, Nikhil
    Yu, Evan Y.
    Xylinas, Evanguelos
    Campain, Nicholas J.
    Kassouf, Wassim
    Dall'Era, Marc A.
    Seah, Jo-An
    Ercole, Cesar E.
    Horenblas, Simon
    Sridhar, Srikala S.
    McGrath, John S.
    Aning, Jonathan
    Wright, Jonathan L.
    Thorpe, Andrew C.
    Morgan, Todd M.
    Holzbeierlein, Jeffrey M.
    Bivalacqua, Trinity J.
    North, Scott
    Barocas, Daniel A.
    Lotan, Yair
    Grivas, Petros
    Stephenson, Andrew J.
    Shah, Jay B.
    van Rhijn, Bas W.
    Daneshmand, Siamak
    Spiess, Philippe E.
    Shariat, Shahrokh F.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (07) : 639.e1 - 639.e9
  • [37] Induction Chemotherapy Followed by Surgery in Node Positive Bladder Cancer
    Meijer, Richard P.
    Mertens, Laura S.
    van Rhijn, Bas W.
    Bex, Axel
    van der Poel, Henk G.
    Meinhardt, Wim
    Kerst, J. Martijn
    Bergman, Andre M.
    Fioole-Bruining, Annemarie
    van Werkhoven, Erik
    Horenblas, Simon
    UROLOGY, 2014, 83 (01) : 134 - 139
  • [38] Neoadjuvant, inductive or adjuvant chemotherapy of bladder cancer
    Ohlmann, C. -H.
    De Santis, M.
    UROLOGE, 2013, 52 (11): : 1534 - +
  • [39] Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer
    Motterle, Giovanni
    Andrews, Jack R.
    Morlacco, Alessandro
    Karnes, R. Jeffrey
    EUROPEAN UROLOGY FOCUS, 2020, 6 (04): : 642 - 649
  • [40] Neoadjuvant, inductive or adjuvant chemotherapy of bladder cancer
    Ohlmann, C. -H.
    De Santis, M.
    UROLOGE, 2013, 52 (11): : 1534 - +
12345